海外の治験の状況「COVID-19」での検索結果
32件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Recruiting
- A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies
- Relapsed or Refractory Hematological Malignancies
- China
- 2019-07-03
Recruiting
- Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19
- ;I21 - Acute myocardial infarction
- Austria, France, Germany, Hungary, Lithuania, Switzerland, Turkey, United Kingdom
- 2015-06-24
Recruiting
- The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
- B-cell Acute Lymphoblastic Leukemia;B-cell Acute Lymphoblastic Leukemia;B-cell Acute Lymphoblastic Leukemia;B-cell Acute Lymphoblastic Leukemia
- China
- 2016-09-29
Recruiting
- CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
- Leukemia, Lymphocytic, Acute;Leukemia, Lymphocytic, Acute;Leukemia, Lymphocytic, Acute
- China
- 2018-05-22
Recruiting
- Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia;Acute Lymphoblastic Leukemia
- China
- 2016-06-16
Recruiting
- A single-center, single-arm, open-label, dose escalation study to evaluate the safety & preliminary anti-tumor activity of CD19 single-chain antibody chimeric antigen receptor T cells (CAR-T-19) for the treatment of patients with relapsed / refractory B-cell leukemia / lymphoma
- Patients with relapsed / refractory B-cell leukaemia / lymphoma
- China
- 2017-11-23
Recruiting
- CART-19 recurrent or refractory source B cell acute lymphoblastic leukemia, single center of safety and effectiveness, single arm, open label, phase II clinical study
- Refractory/recurrent B cell source acute lymphocytic leukemia.
- China
- 2018-09-05
Recruiting
- An open-label, single-center and single-arm clinical study of infusion of anti-CD19 or CD22 CAR-T cells (CT101A-19 or CT102A-22) for patients with relapsed/refractory/high risk B cell malignancies.
- B cell malignancies
- China
- 2019-06-18
Recruiting
- Study to compare two formulations of pegfilgrastim in healthy males
- Healthy Human Volunteers, Age 18-45 years, BMI 19 to 25kg/m2
- India
- 2014-08-04
Recruiting
- CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia
- China
- 2019-03-25